Home > Insider Trading > Filing (0000899243-21-021779)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816213	Yvonne Mcgrath	C/O Iteos Therapeutics, Inc., 139 Main Street Cambridge MA 02142	Vp, Research And Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-24	7,927	$4.23	7,927	No	4	M	Direct
Common Stock	Disposition	2021-05-24	7,927	$21.92	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-05-24	7,927	$0.00	7,927	$4.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
110,977		2030-05-01	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 15, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.32, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
One-fourth of the shares subject to the stock option vest on the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through such date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through each applicable vesting date.